These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Sensitivity of AML Cells with FLT3 Wang YY; Liu CY; Zhang W; He JJ; Su L; Sun WL Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1350-1355. PubMed ID: 29070106 [TBL] [Abstract][Full Text] [Related]
23. Emerging treatments in acute myeloid leukemia: current standards and unmet challenges. Percival ME; Estey E Clin Adv Hematol Oncol; 2017 Aug; 15(8):632-642. PubMed ID: 28949951 [TBL] [Abstract][Full Text] [Related]
24. Midostaurin as the Most Likely Cause of Bilateral Adrenal Masses in a Patient with Acute Myeloid Leukemia. Schutte T; Stege CAM; Smits MM; Franssen LE; Donker ML; de Leeuw DC Clin Drug Investig; 2022 Sep; 42(9):791-797. PubMed ID: 35948754 [No Abstract] [Full Text] [Related]
25. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia. Fathi AT; Chen YB Eur J Haematol; 2017 Apr; 98(4):330-336. PubMed ID: 28000291 [TBL] [Abstract][Full Text] [Related]
26. Midostaurin administration in two hemodialysis patients. Tollkuci E; Seddon A; Geswein L; Mulseh M J Oncol Pharm Pract; 2019 Jul; 25(5):1285-1288. PubMed ID: 30253726 [TBL] [Abstract][Full Text] [Related]
27. Bullous Sweet syndrome in a patient with acute myeloid leukemia treated with midostaurin: Rapid response to acitretin and colchicine-A case report. Chiewchanvit S; Jamjanya S; Rattanathammethee T; Mahanupab P; Tovanabutra N; Chuamanochan M Dermatol Ther; 2021 Nov; 34(6):e15171. PubMed ID: 34676629 [No Abstract] [Full Text] [Related]
28. FLT3 inhibitors for the treatment of acute myeloid leukemia. Wiernik PH Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555 [TBL] [Abstract][Full Text] [Related]
29. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Albers C; Leischner H; Verbeek M; Yu C; Illert AL; Peschel C; von Bubnoff N; Duyster J Leukemia; 2013 Jun; 27(6):1416-8. PubMed ID: 23392356 [No Abstract] [Full Text] [Related]
30. FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Sanz M; Burnett A; Lo-Coco F; Löwenberg B Curr Opin Oncol; 2009 Nov; 21(6):594-600. PubMed ID: 19684517 [TBL] [Abstract][Full Text] [Related]
31. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Hoehn D; Medeiros LJ; Chen SS; Tian T; Jorgensen JL; Ahmed Y; Lin P Am J Clin Pathol; 2012 Feb; 137(2):213-9. PubMed ID: 22261446 [TBL] [Abstract][Full Text] [Related]
32. Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug. He H; Tran P; Gu H; Tedesco V; Zhang J; Lin W; Gatlik E; Klein K; Heimbach T Drug Metab Dispos; 2017 May; 45(5):540-555. PubMed ID: 28270565 [TBL] [Abstract][Full Text] [Related]
33. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia. Garcia JS; Stone RM Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394 [TBL] [Abstract][Full Text] [Related]
35. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cools J; Mentens N; Furet P; Fabbro D; Clark JJ; Griffin JD; Marynen P; Gilliland DG Cancer Res; 2004 Sep; 64(18):6385-9. PubMed ID: 15374944 [TBL] [Abstract][Full Text] [Related]
36. The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations. Odgerel T; Kikuchi J; Wada T; Shimizu R; Futaki K; Kano Y; Furukawa Y Oncogene; 2008 May; 27(22):3102-10. PubMed ID: 18071308 [TBL] [Abstract][Full Text] [Related]
37. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Swords R; Freeman C; Giles F Leukemia; 2012 Oct; 26(10):2176-85. PubMed ID: 22614177 [TBL] [Abstract][Full Text] [Related]
38. [Clinical Characteristics and Prognosis of Acute Myeloid Leukemia with FLT3-ITD Mutation]. Liu Y; Ke XY; Wang J; Wang JJ; Jing HM; Dong F Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):354-358. PubMed ID: 29665898 [TBL] [Abstract][Full Text] [Related]
40. New agents: great expectations not realized. Lancet JE Best Pract Res Clin Haematol; 2013 Sep; 26(3):269-74. PubMed ID: 24309529 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]